Urine Test to Capture Kidney Disease Early Launched
Nephrocor announced the launch of their new RenalVysion test. This test promotes early diagnosis of kidney disease, as described by Siemens’s LabNews.
The test first identifies and then quantifies the amount of sediment contained in a urine specimen. This type of processing is not completed during routine urinalysis testing. Test results are highly specific and can provide localized information about the anatomic location of injury within the kidney. Moreover, test results specify disease severity.
Test results provide pathologists with information that enables distinction between bladder and renal lesions. This is made possible by the integration of quantitative and qualitative urine chemistries, as well as urine cytopathology. The RenalVysion test methods capture abnormalities which would not be noted using Brightfield microscopy.
Results obtained with testing can assist with monitoring the stage of renal disease, either chronic or acute. As well, information can be used to guide diagnostic decision-making and treatment choices. It can also help determine whether or not a biopsy should be completed to procure more information.
The test requires a 30 mL urine sample from patients. The slides are permanently prepared for review, follow-up, and quality control activities. Research indicates that the test has a rate of 91 percent accuracy in diagnosing glomerular disease compared to kidney biopsy.
November 14, 2007 Related topics: Product Launches, Laboratory Equipment, Diagnostic, Renal & Urology